Ghent University Academic Bibliography

Advanced

Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions

VIBEKE KRUSE, Annemie Somers, Lucas Van Bortel, ANNELEEN DE BOTH, Simon Van Belle UGent and Sylvie Rottey UGent (2014) JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 39(3). p.259-265
abstract
What is known and objective Sunitinib, a CYP3A4 substrate, is standard of care treatment in metastatic renal cell carcinoma (mRCC) and is administered orally as a single dose of 50 mg, in a 4 weeks on/2 weeks off regimen. Frequently, dose reduction is necessary because of toxicity, as is the association of comedication to treat side effects. In addition, existing comorbidities in these patients necessitate the intake of various classes of chronic medication. Only limited data are available on the risk of drug–drug interactions (DDI). The objective of our paper was to evaluate prescribed dose, comedication, risk of drug–drug interactions and outcome among patients with mRCC treated with sunitinib. Methods: A single-centre, retrospective analysis was performed for patients with mRCC treated with sunitinib. The drug interaction databases ‘Clinical Pharmacology’© and ‘Lexicomp’© were used to screen for possible interactions. Results and discussion: The hospital files of 36 patients with mRCC were evaluated. Twenty-two patients received sunitinib as first-line treatment. Progression-free survival (PFS) in this first-line group was longer for patients that started with full-dose sunitinib (21·1 months; n = 12) than for patients started on reduced dose (3·5 months; n = 10). In the whole group of 36 patients, an average of 6·8 comedications was taken. Possible pharmacodynamic drug–drug interactions were most frequently found (47%) and reported as major interactions (QT prolongation). Risk of pharmacokinetic interactions due to co-administration of CYP inhibitors, CYP inducers, CYP substrates and PgP substrates was reported for 8%, 11%, 53% and 19%, respectively. These interactions were reported as major or moderate. What is new and conclusion: Patients with mRCC under treatment with sunitinib at a reduced starting dose had a decreased PFS compared with patients started with full-dose sunitinib. Due to adverse drug reactions and comorbidity, patients under sunitinib, a CYP3A4 substrate, took an average of 6·8 comedications provoking an important risk of major-to-moderate drug–drug interactions. With the help of a multidisciplinary team, avoidance of drug–drug interactions could be obtained. Moreover, serial ECG monitoring is recommended for patients at high risk of QT prolongation.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
comedications, metastatic renal cell cancer, adverse drug reactions, sunitinib, drug–drug interactions, INFORMATION DATABASES, ANTICANCER DRUGS, INTERFERON-ALPHA, CARCINOMA, PREVALENCE
journal title
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
J. Clin. Pharm. Ther.
volume
39
issue
3
pages
259 - 265
Web of Science type
Article
Web of Science id
000334679600007
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
1.668 (2014)
JCR rank
171/255 (2014)
JCR quartile
3 (2014)
ISSN
0269-4727
DOI
10.1111/jcpt.12134
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
4251144
handle
http://hdl.handle.net/1854/LU-4251144
date created
2014-01-27 15:37:26
date last changed
2016-12-19 15:45:46
@article{4251144,
  abstract     = {What is known and objective Sunitinib, a CYP3A4 substrate, is standard of care treatment in metastatic renal cell carcinoma (mRCC) and is administered orally as a single dose of 50 mg, in a 4 weeks on/2 weeks off regimen. Frequently, dose reduction is necessary because of toxicity, as is the association of comedication to treat side effects. In addition, existing comorbidities in these patients necessitate the intake of various classes of chronic medication. Only limited data are available on the risk of drug--drug interactions (DDI). The objective of our paper was to evaluate prescribed dose, comedication, risk of drug--drug interactions and outcome among patients with mRCC treated with sunitinib.
Methods: A single-centre, retrospective analysis was performed for patients with mRCC treated with sunitinib. The drug interaction databases {\textquoteleft}Clinical Pharmacology{\textquoteright}{\textcopyright} and {\textquoteleft}Lexicomp{\textquoteright}{\textcopyright} were used to screen for possible interactions.
Results and discussion: The hospital files of 36 patients with mRCC were evaluated. Twenty-two patients received sunitinib as first-line treatment. Progression-free survival (PFS) in this first-line group was longer for patients that started with full-dose sunitinib (21{\textperiodcentered}1 months; n = 12) than for patients started on reduced dose (3{\textperiodcentered}5 months; n = 10). In the whole group of 36 patients, an average of 6{\textperiodcentered}8 comedications was taken. Possible pharmacodynamic drug--drug interactions were most frequently found (47\%) and reported as major interactions (QT prolongation). Risk of pharmacokinetic interactions due to co-administration of CYP inhibitors, CYP inducers, CYP substrates and PgP substrates was reported for 8\%, 11\%, 53\% and 19\%, respectively. These interactions were reported as major or moderate.
What is new and conclusion: Patients with mRCC under treatment with sunitinib at a reduced starting dose had a decreased PFS compared with patients started with full-dose sunitinib. Due to adverse drug reactions and comorbidity, patients under sunitinib, a CYP3A4 substrate, took an average of 6{\textperiodcentered}8 comedications provoking an important risk of major-to-moderate drug--drug interactions. With the help of a multidisciplinary team, avoidance of drug--drug interactions could be obtained. Moreover, serial ECG monitoring is recommended for patients at high risk of QT prolongation.},
  author       = {KRUSE, VIBEKE and Somers, Annemie and Van Bortel, Lucas and DE BOTH, ANNELEEN and Van Belle, Simon and Rottey, Sylvie},
  issn         = {0269-4727},
  journal      = {JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS},
  keyword      = {comedications,metastatic renal cell cancer,adverse drug reactions,sunitinib,drug--drug interactions,INFORMATION DATABASES,ANTICANCER DRUGS,INTERFERON-ALPHA,CARCINOMA,PREVALENCE},
  language     = {eng},
  number       = {3},
  pages        = {259--265},
  title        = {Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions},
  url          = {http://dx.doi.org/10.1111/jcpt.12134},
  volume       = {39},
  year         = {2014},
}

Chicago
KRUSE, VIBEKE, Annemie Somers, Lucas Van Bortel, ANNELEEN DE BOTH, Simon Van Belle, and Sylvie Rottey. 2014. “Sunitinib for Metastatic Renal Cell Cancer Patients: Observational Study Highlighting the Risk of Important Drug-drug Interactions.” Journal of Clinical Pharmacy and Therapeutics 39 (3): 259–265.
APA
KRUSE, V., Somers, A., Van Bortel, L., DE BOTH, A., Van Belle, S., & Rottey, S. (2014). Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 39(3), 259–265.
Vancouver
1.
KRUSE V, Somers A, Van Bortel L, DE BOTH A, Van Belle S, Rottey S. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2014;39(3):259–65.
MLA
KRUSE, VIBEKE, Annemie Somers, Lucas Van Bortel, et al. “Sunitinib for Metastatic Renal Cell Cancer Patients: Observational Study Highlighting the Risk of Important Drug-drug Interactions.” JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 39.3 (2014): 259–265. Print.